Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
The last date to apply for this program is 18th January 2022
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
Subscribe To Our Newsletter & Stay Updated
